Key result
Plasma protein biomarkers predict cardiovascular death risk for at least 15 years in chronic CHD.
Why the study?
It is uncertain whether associations between protein biomarkers reflecting different pathophysiological pathways and adverse cardiovascular events are sustained with increasing years after measurement.
Are plasma protein biomarkers associated with long-term cardiovascular mortality risk in patients with chronic coronary heart disease?
Cohort
Are plasma protein biomarkers associated with long-term cardiovascular mortality risk in patients with chronic coronary heart disease?
Plasma protein biomarkers can predict cardiovascular mortality risk for at least 15 years in patients with chronic coronary heart disease.
Answers are grounded in this paper and cite their sources.
May support extended risk stratification in chronic CHD; hypothesis-generating, requires validation before guiding care.
BACKGROUND: Protein biomarkers that reflect different pathophysiological pathways have been associated with the risk of adverse cardiovascular events. However, it is uncertain whether these associations are sustained with increasing years after the biomarkers are measured. METHODS AND CONCLUSIONS: In patients with chronic coronary heart disease, biomarkers that reflect different pathophysiological pathways are associated with the risk of cardiovascular death for at least the next 15 years.
No takes yet. Share an insight, caveat, or question.
Stewart et al. (2024) conducted a cohort in Chronic coronary heart disease. Plasma protein biomarkers was evaluated on Cardiovascular death (p=<0.001). Plasma protein biomarkers are associated with the risk of cardiovascular death for at least 15 years in patients with chronic coronary heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: